Niacin-Induced Hepatitis: A Potential Side Effect With Low-Dose Time-Release Niacin

JEFF A. ETCHASON; TODD D. MILLER; RAY W. SQUIRES; THOMAS G. ALLISON; GERALD T. GAU; JAMES K. MARTTILA; BRUCE A. KOTTKE

doi:10.1016/S0025-6196(12)61171-9

Niacin-Induced Hepatitis: A Potential Side Effect With Low-Dose Time-Release Niacin

JEFF A. ETCHASON, TODD D. MILLER, RAY W. SQUIRES, THOMAS G. ALLISON, GERALD T. GAU, JAMES K. MARTTILA, BRUCE A. KOTTKE

Cardiovascular Medicine

Research output: Contribution to journal › Article › peer-review

74 Scopus citations

Abstract

Hepatitis developed in five patients who were taking low dosages (3 g/day or less) of time-release niacin. In four of the five patients, clinical symptoms of hepatitis developed after the medication had been taken for a relatively short time (2 days to 7 weeks). This manifestation of hepatotoxicity seems to differ from that previously reported in association with use of crystalline niacin, which occurred with high dosage and prolonged usage of the medication. In view of the recent increased frequency of prescribing niacin for the treatment of hyperlipidemia, physicians should be aware of the potential for hepatotoxicity with even low-dose and short-term use of time-release niacin.

Original language	English (US)
Pages (from-to)	23-28
Number of pages	6
Journal	Mayo Clinic proceedings
Volume	66
Issue number	1
DOIs	https://doi.org/10.1016/S0025-6196(12)61171-9
State	Published - 1991

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/S0025-6196(12)61171-9

Cite this

@article{24c51b6e9ef541fdaa447039820d5aca,

title = "Niacin-Induced Hepatitis: A Potential Side Effect With Low-Dose Time-Release Niacin",

abstract = "Hepatitis developed in five patients who were taking low dosages (3 g/day or less) of time-release niacin. In four of the five patients, clinical symptoms of hepatitis developed after the medication had been taken for a relatively short time (2 days to 7 weeks). This manifestation of hepatotoxicity seems to differ from that previously reported in association with use of crystalline niacin, which occurred with high dosage and prolonged usage of the medication. In view of the recent increased frequency of prescribing niacin for the treatment of hyperlipidemia, physicians should be aware of the potential for hepatotoxicity with even low-dose and short-term use of time-release niacin.",

author = "ETCHASON, {JEFF A.} and MILLER, {TODD D.} and SQUIRES, {RAY W.} and ALLISON, {THOMAS G.} and GAU, {GERALD T.} and MARTTILA, {JAMES K.} and KOTTKE, {BRUCE A.}",

year = "1991",

doi = "10.1016/S0025-6196(12)61171-9",

language = "English (US)",

volume = "66",

pages = "23--28",

journal = "Mayo Clinic proceedings",

issn = "0025-6196",

publisher = "Elsevier Science",

number = "1",

}

TY - JOUR

T1 - Niacin-Induced Hepatitis

T2 - A Potential Side Effect With Low-Dose Time-Release Niacin

AU - ETCHASON, JEFF A.

AU - MILLER, TODD D.

AU - SQUIRES, RAY W.

AU - ALLISON, THOMAS G.

AU - GAU, GERALD T.

AU - MARTTILA, JAMES K.

AU - KOTTKE, BRUCE A.

PY - 1991

Y1 - 1991

N2 - Hepatitis developed in five patients who were taking low dosages (3 g/day or less) of time-release niacin. In four of the five patients, clinical symptoms of hepatitis developed after the medication had been taken for a relatively short time (2 days to 7 weeks). This manifestation of hepatotoxicity seems to differ from that previously reported in association with use of crystalline niacin, which occurred with high dosage and prolonged usage of the medication. In view of the recent increased frequency of prescribing niacin for the treatment of hyperlipidemia, physicians should be aware of the potential for hepatotoxicity with even low-dose and short-term use of time-release niacin.

AB - Hepatitis developed in five patients who were taking low dosages (3 g/day or less) of time-release niacin. In four of the five patients, clinical symptoms of hepatitis developed after the medication had been taken for a relatively short time (2 days to 7 weeks). This manifestation of hepatotoxicity seems to differ from that previously reported in association with use of crystalline niacin, which occurred with high dosage and prolonged usage of the medication. In view of the recent increased frequency of prescribing niacin for the treatment of hyperlipidemia, physicians should be aware of the potential for hepatotoxicity with even low-dose and short-term use of time-release niacin.

UR - http://www.scopus.com/inward/record.url?scp=0026061832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026061832&partnerID=8YFLogxK

U2 - 10.1016/S0025-6196(12)61171-9

DO - 10.1016/S0025-6196(12)61171-9

M3 - Article

C2 - 1988755

AN - SCOPUS:0026061832

SN - 0025-6196

VL - 66

SP - 23

EP - 28

JO - Mayo Clinic proceedings

JF - Mayo Clinic proceedings

IS - 1

ER -

Niacin-Induced Hepatitis: A Potential Side Effect With Low-Dose Time-Release Niacin

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this